As of March 2024 AVEO Oncology has a market cap of $0.52 Billion. This makes AVEO Oncology the world's 5982th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Market cap | Change |
---|---|---|
2024 | $0.52 B | 0% |
2023 | $0.52 B | 0.33% |
2022 | $0.51 B | 222.37% |
2021 | $0.16 B | -3.02% |
2020 | $0.16 B | 65.57% |
2019 | $0.10 B | -50.39% |
2018 | $0.20 B | -38.7% |
2017 | $0.33 B | 705.83% |
2016 | $40.96 M | -44.12% |
2015 | $73.3 M | 66.87% |
2014 | $43.93 M | -53.66% |
2013 | $94.81 M | -73.1% |
2012 | $0.35 B | -52.57% |
2011 | $0.74 B | 42.75% |
2010 | $0.52 B |
Name | Market cap | Market cap differencediff. | Country |
---|---|---|---|
Eli Lilly LLY | $751.97 B | 144,110.36% | ๐บ๐ธ USA |
Amgen AMGN | $153.17 B | 29,274.25% | ๐บ๐ธ USA |
Biogen BIIB | $31.23 B | 5,889.13% | ๐บ๐ธ USA |
Regeneron Pharmaceuticals REGN | $105.38 B | 20,109.65% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $108.41 B | 20,692.11% | ๐บ๐ธ USA |
Merrimack Pharmaceuticals MACK | $0.21 B | -58.81% | ๐บ๐ธ USA |